Stay updated with breaking news from Multicenter Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SEATTLE, Dec. 05, 2023 -- Adaptive Biotechnologies Corporation , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to...
Comprehensive program focused on innovation in AI – hosted jointly by teams from Calantic Digital Solutions and Blackford Analysis
Investigators believe targeted immunomodulation with SEL-212 may have the potential to introduce a new uricase-based therapy for patients with gout refractory to conventional treatment.
39 presentations span ten medicines, including six in Pfizer’s pipeline, being studied for the treatment of hemophilia, sickle cell disease, and blood cancer Presentations include primary...
The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and...